SHENZHEN, China: Chinese handset rivals of Huawei Technologies including Xiaomi, Oppo and Vivo are making aggressive moves to seize market share from their giant rival, after stepped-up U.S. sanctions hobbled Huawei's supply chains, industry insiders say.
Last week Huawei said it had sold its budget brand smartphone unit Honor for an undisclosed sum in a bid to safeguard the latter's supply chain from U.S. action, which has made it difficult to source essential components.
All the same, Huawei's Chinese rivals smell blood in the mid- to high-end phone market. In August a Huawei executive said the company will not be able to produce its flagship processors that power its high-end smartphones.
"What we can see now, whether from Xiaomi, Oppo or Vivo, is that they're raising their forecasts for next year," said Derek Wang, an executive in charge of production at handset maker Realme, which shares a supply chain with Oppo.
"They believe the sanctions against Huawei will more or less hurt it in the international market, and they may want to take a share of the market from Huawei."
Founded in 2018, Realme is on course to double its smartphone shipments to 50 million this year, Wang said. It has built a base with low price-offerings in Southeast Asia and India, and is looking to target Europe and China next year with a push into the high-end market, regardless of Huawei's situation, Wang said.
In August, the U.S. Commerce Department further choked Huawei's access to U.S. technology essential to its handset business, on the grounds that Huawei poses a security threat - a charge Huawei denies.
Huawei briefly overtook Samsung as the world's biggest handset maker in the first half of this year, before shipments fell 23per cent to 51.7 million units in the third quarter, according to research firm Canalys.
Huawei still commanded 41.2per cent of the market in the third quarter, followed by Vivo with 18.4per cent, Oppo with 16.8per cent and Xiaomi with 12.6per cent, Canalys said. Apple has a lower share in China with 6.2per cent, but is attracting strong demand for its 5G iPhone 12, Canalys said.
China Smartphone Shipments, Q3 2020 (Millions) https://graphics.reuters.com/CHINA-MOBILE/HUAWE-COMPETITORS/nmopadbnava/chart.png
Industry watchers have confirmed a ramping up of orders from vendors. Xiaomi has been most bullish, placing enough orders for up to 100 million phones between the fourth quarter of 2020 and first quarter of 2021, up 50per cent on projections before the August restrictions, consultancy Isaiah Research says.
Oppo and Vivo's production forecasts had also risen by around 8per cent each since August, with orders for up to 90 million and 70 million handsets respectively, Isaiah Research's data showed.
Conversely, Huawei orders fell 55per cent to 42 million handsets in that time.
All four companies declined to comment on the numbers.
Xiaomi is also attempting to court Huawei's distributors in Southeast Asia and Europe in the hopes of gaining exclusive deals, and is actively targeting Huawei's high-end market share in China, said a source at Xiaomi familiar with the matter.
Five industry sources on the supply chain side confirmed they had a surge in orders from the three companies.
Some analysts believe the companies might be too optimistic about their targets, but Realme's Wang said stockpiling of components have also been driven by disruption to production caused by COVID-19 lockdowns earlier in the year and because Huawei's move to boost its inventories impacted rivals' supply chains.
The rush to secure supplies has reverberated across the electronics chain, said Paul Weedman, a supply chain project manager. "Prices have been rocketing recently," he said, noting that it has become much harder to source LCD screens even for tablets.
Analysts said Huawei's sale of Honor may partly fend off competitors' intrusion into the budget-end of the market, provided that Honor is able to resume sourcing U.S. technology.
"We still expect clear year-on-year growth from Huawei and Honor's smartphone rivals in 2021, but likely at a lower ratio than their earliest expectation." said Flora Tang, an analyst with research firm Counterpoint.
(Reporting by David Kirton; Editing by Shri Navaratnam and Emelia Sithole-Matarise)